iRhythm Technologies, Inc. (NASDAQ:IRTC) Expected to Post Earnings of -$0.95 Per Share

Equities research analysts expect iRhythm Technologies, Inc. (NASDAQ:IRTCGet Rating) to report earnings of ($0.95) per share for the current quarter, according to Zacks. Five analysts have made estimates for iRhythm Technologies’ earnings, with the lowest EPS estimate coming in at ($1.00) and the highest estimate coming in at ($0.89). iRhythm Technologies posted earnings per share of ($0.59) during the same quarter last year, which indicates a negative year-over-year growth rate of 61%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that iRhythm Technologies will report full-year earnings of ($3.28) per share for the current year, with EPS estimates ranging from ($3.43) to ($3.11). For the next financial year, analysts expect that the company will report earnings of ($1.99) per share, with EPS estimates ranging from ($2.62) to ($1.70). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for iRhythm Technologies.

iRhythm Technologies (NASDAQ:IRTCGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.26. iRhythm Technologies had a negative return on equity of 34.55% and a negative net margin of 36.43%. The company had revenue of $92.40 million for the quarter, compared to analyst estimates of $86.76 million. During the same period last year, the company posted ($0.95) earnings per share. The firm’s revenue was up 24.4% compared to the same quarter last year.

A number of research firms recently commented on IRTC. Citigroup downgraded iRhythm Technologies from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday. JPMorgan Chase & Co. lifted their target price on iRhythm Technologies from $156.00 to $192.00 and gave the company an “overweight” rating in a research note on Monday, April 4th. Needham & Company LLC upgraded iRhythm Technologies from a “hold” rating to a “buy” rating and set a $135.00 target price for the company in a research note on Thursday, February 24th. Zacks Investment Research downgraded iRhythm Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, StockNews.com assumed coverage on iRhythm Technologies in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, iRhythm Technologies has an average rating of “Buy” and a consensus target price of $159.54.

NASDAQ:IRTC traded down $11.19 during mid-day trading on Thursday, reaching $138.03. The stock had a trading volume of 611,328 shares, compared to its average volume of 377,239. The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of -32.79 and a beta of 1.23. iRhythm Technologies has a 1-year low of $41.66 and a 1-year high of $169.54. The stock’s 50 day simple moving average is $138.48 and its two-hundred day simple moving average is $126.78. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.63 and a quick ratio of 4.43.

A number of hedge funds and other institutional investors have recently bought and sold shares of IRTC. LTS One Management LP bought a new position in iRhythm Technologies during the fourth quarter valued at about $94,152,000. Capital Research Global Investors raised its holdings in iRhythm Technologies by 777.0% during the fourth quarter. Capital Research Global Investors now owns 877,000 shares of the company’s stock valued at $103,214,000 after buying an additional 777,000 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in iRhythm Technologies during the first quarter valued at about $84,724,000. Camber Capital Management LP acquired a new stake in shares of iRhythm Technologies in the third quarter valued at about $27,816,000. Finally, Norges Bank acquired a new stake in shares of iRhythm Technologies in the fourth quarter valued at about $39,354,000. Institutional investors own 97.92% of the company’s stock.

iRhythm Technologies Company Profile (Get Rating)

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Featured Stories

Get a free copy of the Zacks research report on iRhythm Technologies (IRTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for iRhythm Technologies (NASDAQ:IRTC)

Want More Great Investing Ideas?

Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.